CA1255589A - Materiel pour implant en collagene reticule injectable - Google Patents

Materiel pour implant en collagene reticule injectable

Info

Publication number: CA1255589A
Authority: CA; Canada
Prior art keywords: collagen; cross; linked; log; linking
Prior art date: 1986-01-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000500548A

Other languages

English (en)

Inventor

Thomas L. Smestad

John Mcpherson

Donald G. Wallace

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Collagen Aesthetics Inc

Original Assignee

Collagen Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-01-28

Filing date

1986-01-28

Publication date

1989-06-13

1986-01-28 Application filed by Collagen Corp filed Critical Collagen Corp

1986-01-28 Priority to CA000500548A priority Critical patent/CA1255589A/fr

1989-06-13 Application granted granted Critical

1989-06-13 Publication of CA1255589A publication Critical patent/CA1255589A/fr

Status Expired legal-status Critical Current

Links

239000000463 material Substances 0.000 title claims description 47
239000000501 collagen implant Substances 0.000 title claims description 17
102000008186 Collagen Human genes 0.000 claims abstract description 122
108010035532 Collagen Proteins 0.000 claims abstract description 122
229920001436 collagen Polymers 0.000 claims abstract description 120
238000004132 cross linking Methods 0.000 claims abstract description 24
239000000725 suspension Substances 0.000 claims abstract description 23
239000000243 solution Substances 0.000 claims abstract description 21
239000003431 cross linking reagent Substances 0.000 claims abstract description 19
238000010791 quenching Methods 0.000 claims abstract description 12
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims abstract description 11
230000000171 quenching effect Effects 0.000 claims abstract description 11
210000004872 soft tissue Anatomy 0.000 claims abstract description 10
239000002504 physiological saline solution Substances 0.000 claims abstract description 7
239000011541 reaction mixture Substances 0.000 claims abstract description 7
125000000539 amino acid group Chemical group 0.000 claims abstract description 6
239000012736 aqueous medium Substances 0.000 claims abstract description 5
230000003472 neutralizing effect Effects 0.000 claims abstract description 3
238000000034 method Methods 0.000 claims description 23
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical group O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 18
150000001299 aldehydes Chemical group 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 13
238000006243 chemical reaction Methods 0.000 claims description 12
230000003190 augmentative effect Effects 0.000 claims description 10
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 9
239000002245 particle Substances 0.000 claims description 9
241000124008 Mammalia Species 0.000 claims description 6
241000283690 Bos taurus Species 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 5
239000004472 Lysine Substances 0.000 claims description 3
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 3
230000002378 acidificating effect Effects 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
239000007900 aqueous suspension Substances 0.000 claims 5
239000007795 chemical reaction product Substances 0.000 claims 2
238000000926 separation method Methods 0.000 claims 2
238000005406 washing Methods 0.000 claims 2
239000007864 aqueous solution Substances 0.000 claims 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
239000000376 reactant Substances 0.000 claims 1
239000007943 implant Substances 0.000 abstract description 22
239000000835 fiber Substances 0.000 abstract description 11
230000003416 augmentation Effects 0.000 abstract description 5
230000002688 persistence Effects 0.000 abstract description 5
150000001413 amino acids Chemical class 0.000 abstract description 3
230000002500 effect on skin Effects 0.000 abstract description 3
238000002360 preparation method Methods 0.000 description 23
229960000587 glutaral Drugs 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 12
102000004190 Enzymes Human genes 0.000 description 12
229940088598 enzyme Drugs 0.000 description 12
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
150000002500 ions Chemical class 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
239000000203 mixture Substances 0.000 description 8
239000006185 dispersion Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000003491 skin Anatomy 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000002253 acid Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000002513 implantation Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
210000004027 cell Anatomy 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
238000005755 formation reaction Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000007928 solubilization Effects 0.000 description 4
238000005063 solubilization Methods 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229960003767 alanine Drugs 0.000 description 3
230000007547 defect Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000001914 filtration Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
235000018977 lysine Nutrition 0.000 description 3
HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 3
238000004062 sedimentation Methods 0.000 description 3
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
206010003694 Atrophy Diseases 0.000 description 2
206010010356 Congenital anomaly Diseases 0.000 description 2
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
241001505295 Eros Species 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
206010040954 Skin wrinkling Diseases 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
229940024606 amino acid Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000037444 atrophy Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
229940012193 contrave Drugs 0.000 description 2
239000012530 fluid Substances 0.000 description 2
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000003589 local anesthetic agent Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000008439 repair process Effects 0.000 description 2
WTGQALLALWYDJH-WYHSTMEOSA-N scopolamine hydrobromide Chemical compound Br.C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-WYHSTMEOSA-N 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000012360 testing method Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 1
101100328895 Caenorhabditis elegans rol-8 gene Proteins 0.000 description 1
241001012508 Carpiodes cyprinus Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000237074 Centris Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
206010009269 Cleft palate Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
229920002085 Dialdehyde starch Polymers 0.000 description 1
208000002021 Enophthalmos Diseases 0.000 description 1
241000720950 Gluta Species 0.000 description 1
239000005909 Kieselgur Substances 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
208000000185 Localized scleroderma Diseases 0.000 description 1
206010027982 Morphoea Diseases 0.000 description 1
206010061875 Nose deformity Diseases 0.000 description 1
241001400033 Omia Species 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
241001466077 Salina Species 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
208000006812 Velopharyngeal Insufficiency Diseases 0.000 description 1
206010066790 Velopharyngeal incompetence Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
-1 acetic Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
206010000496 acne Diseases 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003172 aldehyde group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
238000013098 chemical test method Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
239000012612 commercial material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
208000002980 facial hemiatrophy Diseases 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
229940015043 glyoxal Drugs 0.000 description 1
238000000227 grinding Methods 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
208000016809 linear scleroderma Diseases 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
210000001724 microfibril Anatomy 0.000 description 1
238000003801 milling Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000003254 palate Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000000518 rheometry Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
238000007790 scraping Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000002791 soaking Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000012421 spiking Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1

Landscapes

Materials For Medical Uses (AREA)

CA000500548A 1986-01-28 1986-01-28 Materiel pour implant en collagene reticule injectable Expired CA1255589A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000500548A CA1255589A (fr)	1986-01-28	1986-01-28	Materiel pour implant en collagene reticule injectable

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA000500548A CA1255589A (fr)	1986-01-28	1986-01-28	Materiel pour implant en collagene reticule injectable

Publications (1)

Publication Number	Publication Date
CA1255589A true CA1255589A (fr)	1989-06-13

Family

ID=4132359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000500548A Expired CA1255589A (fr)	1986-01-28	1986-01-28	Materiel pour implant en collagene reticule injectable

Country Status (1)

Country	Link
CA (1)	CA1255589A (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113768815A (zh) *	2021-09-13	2021-12-10	浙江崇山生物制品有限公司	一种胶原蛋白植入剂及其制备方法
CN116879198A (zh) *	2023-06-30	2023-10-13	浙江诸暨聚源生物技术有限公司	交联重组胶原蛋白防粘连膜中edac残留量的检测方法

1986
- 1986-01-28 CA CA000500548A patent/CA1255589A/fr not_active Expired

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113768815A (zh) *	2021-09-13	2021-12-10	浙江崇山生物制品有限公司	一种胶原蛋白植入剂及其制备方法
CN113768815B (zh) *	2021-09-13	2022-08-09	浙江崇山生物制品有限公司	一种胶原蛋白植入剂及其制备方法
CN116879198A (zh) *	2023-06-30	2023-10-13	浙江诸暨聚源生物技术有限公司	交联重组胶原蛋白防粘连膜中edac残留量的检测方法

Legal Events

Date	Code	Title	Description
2006-06-13	MKEX	Expiry

Publication	Publication Date	Title
US4582640A (en)	1986-04-15	Injectable cross-linked collagen implant material
EP0632820B1 (fr)	2000-05-17	Compositions de collagene tres concentre homogeneise
EP0083868B1 (fr)	1986-04-30	Matériau pour implant à base de collagène pour l'augmentation du tissu mou
CA1224210A (fr)	1987-07-14	Implant injectable forme de collagene reticule
CA1279010C (fr)	1991-01-15	Composes de collagene pour la reparation des os contenant de la moelle antogene
US4505855A (en)	1985-03-19	Transparent non-fibrilized collagen material by ultracentrifugation
US8338375B2 (en)	2012-12-25	Packaged product
US4581030A (en)	1986-04-08	Collagen replacement prothesis for the cornea
EP0376931B1 (fr)	1994-06-15	Procédé de fabrication de membranes de collagène à usage médical
CA1336812C (fr)	1995-08-29	Traitement du collagene humain et son utilisation pour les auto-implants
US5314874A (en)	1994-05-24	Intracorporeally injectable composition for implanting highly concentrated cross-linked atelocollagen
US5137875A (en)	1992-08-11	Hyaluronic acid-containing aqueous solution or aqueous dispersion of collagen
CA1260650A (fr)	1989-09-26	Procede de preparation de collagene malleable et produit ainsi obtenu
EP0196197A2 (fr)	1986-10-01	Implant de collagène et méthode pour sa préparation
JP2002524209A (ja)	2002-08-06	膠原組織組成物
US5138030A (en)	1992-08-11	Process for extracting type I collagen form an avian source, and applications therefor
CA2285235A1 (fr)	1998-10-15	Procede ameliore pour fabriquer du collagene
CN118045232A (zh)	2024-05-17	一种医美注射填充材料及其制备方法
CA1255589A (fr)	1989-06-13	Materiel pour implant en collagene reticule injectable
EP0268421A2 (fr)	1988-05-25	Composition pour implant et procédé de préparation de cette composition
JP3008034B2 (ja)	2000-02-14	体内注入可能な高濃度架橋化アテロコラ−ゲン移植用組成物
JPH0136840B2 (fr)	1989-08-02
KR20240005757A (ko)	2024-01-12	세포 담체로서 유용한 콜라겐 하이드로겔
Ellis et al.	1996	Tissue regeneration by use of analogs of extracellular matrix
Bronzino et al.	2006	Biologic Biomaterials: Tissue-Derived Biomaterials (Collagen)